ArticleCureus2026
Statin Use Is Associated With Disseminated Superficial Actinic Porokeratosis: A Population-Based Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are lipid-lowering drugs that block 3-hydroxy-3-methylglutaryl-coenzyme A reductase to prevent atherosclerotic cardiovascular disease. While statins are generally well tolerated, they have been linked to a variety of dermatological disorders. This study investigated the relationship between statin use and disseminated superficial actinic porokeratosis (DSAP), a chronic hereditary skin condition marked by hyperkeratotic papules with characteristic ridge-like borders. Using the TriNetX database, we conducted a retrospective cohort study of 970,166 statin medication patients identified by RxNorm codes. DSAP cases were identified using diagnostic codes, and propensity score matching was used to balance demographic variables between the treatment and control groups. Among statin-treated patients, 660 (0.068%) cases of DSAP were found, compared with 478 (0.049%) cases in controls. Statin medication was linked to a significant increase in DSAP risk (RR, 1.381; 95% CI, 1.227-1.553; p=0.0001). This study finds a statistically significant correlation between statin use and DSAP, emphasizing the significance of monitoring for dermatologic side effects in statin-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.